Lymphoma

Protocols

A-D ---------------------------- ABVD - L.8 Acalabrutinib Monotherapy - L.124 Alemtuzumab - L.88 BCNU Thiotepa (high dose) (B.35) BEACOPP-14 or BEACOPP Escalated - L.18 BEACOPDac-14 or BEACOPDac-Escalated - L.95 Bendamustine-R for CLL - L.44 Bendamustine-R for NHL - L.45 Bexarotene - L.99 Brentuximab vedotin - L. 9 Brentuximab vedotin in combination with CHP - L. 127 Chlorambucil +/- R - L.26 ChlVPP - L.79 CHOEP-21 - L.97 CHOP-14 / R-CHOP - L.48 CHOP-21 / R-CHOP-21 - L. 80 Cladribine - L.28 Cyclophosphamide Oral (L.134) Cytarabine (high dose) +/- R (L.54) Cytarabine (intrathecal) (L.55) DA-EPOCH-R (L.66) DDGP (L.112) DepoCyte - L.57 DRC - L.17 Doxorubicin for urgent use - L.58

E-O ---------------------------- Epcoritamab - L.151 ESHAP / R-ESHAP - L.35 Etoposide/Dexamethasone HLH - L.89 Filgrastim - biosimilar - B.36 Flu/Cy R IV - L.29 Flu/Cy R oral - L.10 Gemcitibine Monotherapy - L.128 Glofitamab EAMS - L.149 High dose methylprednisolone - L.27 Ibrutinib - L.38 Ibrutinib + Ventoclax - L.148 Idelalsib + Rituximab - L.7 IxaDexRitux - L.131 Loncastuximab tesirine (Lonca-T) - L.150 Modified R-ICE - L.116 MATRix - L.33 MaxiCHOP / Ara-C + R - L.84 Methotrexate (high dose) for CNS prophylaxis - L.13 Methotrexate (intrathecal) - L.85 Methotrexate (weekly) - L.87 Methyl-prednisolone (high dose) - L.27 Mini-BEAM (modified) - L.30 Mogamulizumab - L.139 Nivolumab - L.90 Obinutuzumab and Bendamustine - L.91 O-CVP with Maintenance Obinutuzumab - L.98 Obinutuzumab and Chlorambucil - L.22

P-Z ---------------------------- Pembrolizumab - L. 105 Pentostatin - L. 15 PEP-C - L. 107 PMITCEBO-R - L. 52 Pola-R-CHP - L.144 Polatuzumab vedotin +Bendamustin +Rituximab (PBR) - L. 113 R-BAC - L.19 R-CHOP-21 / CHOP-21 - L.80 R-CODOX-M / R-IVAC - L.49 R-CP - L.81 R-CVP - L.82 R-DHAOx (L.133) R-DHAP (L.106) ESHAP / R-ESHAP (L.35) R-FMD (L.115) R-GCVP - L.31 R-GDP - L.62 R-GEMOx - L.100 R-Hyper-CVAD / R-MA - L.51 R-ICE - L.24 R-IVE - L.114 R-MiniCHOP - L. 83 R-VP - L.40 Rituximab Lenalidomide - L.122 Rituximab (maintenance) - L.41 Rituximab (single agent) - L.43 Rituximab Subcutaneous (ARCHIVED) --> Now in L.41 (linked) SMILE (L.67) Temozolamide - L.63 Topotecan / Carboplatin / Thiotepa (TopCaT) - B.48 R-Venetoclax - L.111 Venetoclax and Obinutuzumab - L.130 Zanubrutinib - L.136

For a blank protocol template please click here.

Protocol Care Plans

A-D ---------------------------- BCNU Thiotepa for autograft (N.96) B-GEM conditioning (N.95) ChlVPP Cladribine (N.48) CNOP CODOX-M (N.11) CODOX-M-MTX (N.58)

E-O ---------------------------- ESHAP (N.33) Gazyvaro (Obinutuzumab) GA101 (N.104) GEM-P Day 15 (N.77) High-dose methotrexate (N.24) Hyper-CVAD ICE (N.64) IV Pentamidine (N.73) IVAC - Ly10 (N.20) Joint Apheresis, Dialysis Patients & Line Management (S5.2) Methotrexate (high dose) (N.24) Mini BEAM Ofatumumab Nursing Care Plan (N.118) Oral mucositis (N.26) Oral mucositis assessment - admission

P-Z ---------------------------- Plexifor Protocol Nursing Care Plan (N.113) PMitCEBO Regeneration (N.57) Rituximab infusion rate - 500 mg (N.28a) Rituximab infusion rate - 600 mg (N.28b) Rituximab infusion rate - 700 mg (N.28c) Rituximab infusion rate - 800 mg (N.28d) Rituximab rapid infusion (N.28e)

For a blank protocol care plan template please click here.

Supportive Care

Please Choose ---------------------------- L.101 Bleomycin Supportive Care Guidelines Urgent Sperm Storage Referral Prior to Chemo/Radiotherapy Ovarian Tissue Cryopreservation (OTCP) Referral Form (OVF03)

Patient Information

Please Choose ---------------------------- After your bone marrow biopsy (OMI 61577P) CAR-T Cell Information for Patients (L.121) CLL CNS New Patient Information Sheet (L.102) Having a bone marrow test (OMI 60513P) Lymphoma Telemed Invite Letter (L.73) OUH Vaccination Letter to GPs Treatment Pathway for cHL Early Stage Disease (LPW.20.1) Treatment Pathway for cHL Advanced Stage Disease (LPW.20.2) Clinical Nurse Specialist and Key Worker Booklet

Resources for Primary Care

Please Choose ---------------------------- CLL Guide for GPs Managing Stage A Patients (L.68) CLL GP Notification and Checklist (LPR.116) Lymphoma GP Notification and Checklist (LPR.116) Example letter to Dentist (H.83a)